Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year

Summary

This phase II trial studies how well lopinavir/ritonavir works in treating COVID-19 positive patients with cancer and a weakened immune system (immune-suppression) in the last year and have mild or moderate symptoms caused by COVID-19. Lopinavir/ritonavir may help to lessen or prevent COVID-19 symptoms from getting worse in cancer patients.

Timeline

Start

2021-05-01

Primary completion

2021-11-01

Completion

2021-11-01

Outcome

Outcome not reported

Stopped: “limited resources”

Drugs

Indications